Nektar Reports Q3 2026 Financial Results
Nektar reported $952.9M in cash and $9.4M in revenue for Q3 2026, with Rezpegaldesleukin advancing to Phase 3 development for autoimmune conditions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed